Tuberc Respir Dis > Accepted Articles
DOI: https://doi.org/10.4046/trd.2023.0015    [Accepted]
Published online April 11, 2023.
COPD AND THE AIRWAY MICROBIOME: WHAT RESPIROLOGISTS NEED TO KNOW
Don D. Sin, MD, MPH
Centre for Heart Lung Innovation, St. Paul’s Hospital and University of British Columbia Division of Respiratory Medicine, Vancouver, BC, Canada
Correspondence:  Don D. Sin,
Email: don.sin@hli.ubc.ca
Received: 31 January 2023   • Revised: 27 March 2023   • Accepted: 10 April 2023
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. The lower airways contain a rich and diverse microbiome, which may play a significant regulatory role in both health and disease. In COPD, the microbiome becomes perturbed, causing dysbiosis. Increased representation of members in the Proteobacteria phylum and certain members in the Firmicutes phylum has been associated with increased risk of exacerbations and mortality. Therapies such as inhaled corticosteroids and azithromycin may modulate the airway microbiome or its metabolites in patients with COPD. This paper provides an up-to-date overview of the airway microbiome and its importance in the pathophysiology of COPD and as potential therapeutic target in the future.
Key Words: COPD, airway microbiome, dysbiosis, sequencing
TOOLS
METRICS Graph View
  • 0 Crossref
  •   Scopus
  • 334 View
  • 48 Download
Related articles


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2023 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next